Trial Profile
A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With Nonalcoholic Steatohepatitis (NASH) With Open-Label Part to Evaluate the Safety, PK and Treatment Response Kinetics of Aramchol. The ARMOR Study
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Icomidocholic acid (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Registrational; Therapeutic Use
- Acronyms ARMOR
- Sponsors Galmed Research and Development, Ltd.
- 15 Oct 2023 The trial has been discontinued in Spain, according to European Clinical Trials Database
- 04 Jan 2023 According to a Galmed Pharmaceuticals media release, the company has no plans to start the Double-Blind part of the study.
- 04 Jan 2023 Open-Label Part results (n=157) published in a Galmed Pharmaceuticals media release.